The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Open accessAbstract
FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation. The most clinically important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic factor in acute myeloid leukemia (AML) patients. There are two major types of FLT3 mutations: internal tandem duplication mutations in the juxtamembrane domain (FLT3‐ITD) and point mutations or deletion in the tyrosine kinase domain (FLT3‐TKD). Both mutant FLT3 molecules are activated through ligand‐independent dimerization and trans‐phosphorylation. Mutant FLT3 induces the activation of multiple intracellular signaling pathways, mainly STAT5, MAPK and AKT signals, leading to cell proliferation and anti–apoptosis. Because high‐dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clinical development of FLT3 kinase inhibitors expected. Although several FLT3 inhibitors have been developed, it takes more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clinically available for AML patients with FLT3 mutations. To date, three FLT3 inhibitors have been clinically approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Europe and United states. However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clinical trials. The resistance mechanisms are complex and emerging resistant clones are heterogenous. Further basic and clinical studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Self-citationValidation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 735
Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., & Naoe, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203354 · Cited by 579
Self-citationCore-binding factors in haematopoiesis and leukaemia
Speck, N. A., & Gilliland, D. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc840 · Cited by 569
Lyman, S. D., James, L., Bos, T. V., de Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L. T., Picha, K. S., McKenna, H. J., Splett, R. R., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90325-k · Cited by 527
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Perl, A. E., Altman, J. K., Cortes, J., Smith, C., Litzow, M., Baer, M. R., Claxton, D., Erba, H. P., Gill, S., Goldberg, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30416-3 · Cited by 490
Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487
Cortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30150-0 · Cited by 485
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
Self-citationKiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., & Naoe, T. (1998) · Leukemia · doi:10.1038/sj.leu.2401130 · Cited by 453
Self-citationMcMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
Hannum, C., Culpepper, J., Campbell, D., McClanahan, T., Zurawski, S., Kastelein, R., Bazan, J. F., Hudak, S., Wagner, J., Mattson, J., et al. (1994) · Nature · doi:10.1038/368643a0 · Cited by 439
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.459 · Cited by 429
Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Ravandi, F., Cortes, J. E., Jones, D., Faderl, S., Garcia-Manero, G., Konopleva, M. Y., O'Brien, S., Estrov, Z., Borthakur, G., Thomas, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4888 · Cited by 356
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
Rosnet, O., Schiff, C., Pebusque, M., Marchetto, S., Tonnelle, C., Toiron, Y., Birg, F., & Birnbaum, D. (1993) · Blood · doi:10.1182/blood.v82.4.1110.1110 · Cited by 349
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia
Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400756 · Cited by 344
Self-citationPML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J., & Gilliland, D. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122233699 · Cited by 322
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Kelly, L. M., Yu, J.-C., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I., Amaral, S. M., Curley, D. P., Duclos, N., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00070-3 · Cited by 305
Mathew, N. R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M., Müller, T. A., Hanke, K., Taromi, S., Apostolova, P., et al. (2018) · Nature Medicine · doi:10.1038/nm.4484 · Cited by 295
Kiyoi, H., Ohno, R., Ueda, R., Saito, H., & Naoe, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205332 · Cited by 292
Self-citationYanada, M., Matsuo, K., Suzuki, T., Kiyoi, H., & Naoe, T. (2005) · Leukemia · doi:10.1038/sj.leu.2403838 · Cited by 289
Self-citationPreclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lee, L. Y., Hernandez, D., Rajkhowa, T., Smith, S. C., Raman, J. R., Nguyen, B., Small, D., & Levis, M. (2017) · Blood · doi:10.1182/blood-2016-10-745133 · Cited by 280
Cortes, J., Perl, A. E., Döhner, H., Kantarjian, H., Martinelli, G., Kovacsovics, T., Rousselot, P., Steffen, B., Dombret, H., Estey, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30240-7 · Cited by 266
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Sato, T., Yang, X., Knapper, S., White, P., Smith, B. D., Galkin, S., Small, D., Burnett, A., & Levis, M. (2011) · Blood · doi:10.1182/blood-2010-01-266742 · Cited by 261
Mori, M., Kaneko, N., Ueno, Y., Yamada, M., Tanaka, R., Saito, R., Shimada, I., Mori, K., & Kuromitsu, S. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0470-z · Cited by 258
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Galanis, A., Ma, H., Rajkhowa, T., Ramachandran, A., Small, D., Cortes, J., & Levis, M. (2014) · Blood · doi:10.1182/blood-2013-10-529313 · Cited by 252
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Duployez, N., Marceau-Renaut, A., Boissel, N., Petit, A., Bucci, M., Geffroy, S., Lapillonne, H., Renneville, A., Ragu, C., Figeac, M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-688705 · Cited by 250
Kihara, R., Nagata, Y., Kiyoi, H., Kato, T., Yamamoto, E., Suzuki, K., Chen, F., Asou, N., Ohtake, S., Miyawaki, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.55 · Cited by 237
Self-citationCrenolanib is a selective type I pan-FLT3 inhibitor
Smith, C. C., Lasater, E. A., Lin, K. C., Wang, Q., McCreery, M. Q., Stewart, W. K., Damon, L. E., Perl, A. E., Jeschke, G. R., Sugita, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320661111 · Cited by 211
Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400770 · Cited by 209
Levis, M., Brown, P., Smith, B. D., Stine, A., Pham, R., Stone, R., DeAngelo, D., Galinsky, I., Giles, F., Estey, E., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015743 · Cited by 199
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T., Chin, C.-S., Asthana, S., Olshen, A., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 184
Noguera, N., Breccia, M., Divona, M., Diverio, D., Costa, V, De Santis, S., Avvisati, G., Pinazzi, M., Petti, M., Mandelli, F., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402723 · Cited by 183
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Traer, E., Martinez, J., Javidi-Sharifi, N., Agarwal, A., Dunlap, J., English, I., Kovacsovics, T., Tyner, J. W., Wong, M., & Druker, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3569 · Cited by 165
Park, I.-K., Mundy-Bosse, B., Whitman, S. P., Zhang, X., Warner, S. L., Bearss, D. J., Blum, W., Marcucci, G., & Caligiuri, M. A. (2015) · Leukemia · doi:10.1038/leu.2015.147 · Cited by 164
Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
Rosnet, O., Matteï, M.-G., Marchetto, S., & Birnbaum, D. (1991) · Genomics · doi:10.1016/0888-7543(91)90270-o · Cited by 161
Yamaura, T., Nakatani, T., Uda, K., Ogura, H., Shin, W., Kurokawa, N., Saito, K., Fujikawa, N., Date, T., Takasaki, M., et al. (2017) · Blood · doi:10.1182/blood-2017-05-786657 · Cited by 158
Self-citationClinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Zhang, H., Savage, S. L., Schultz, A. R., Bottomly, D., White, L., Segerdell, E., Wilmot, B., McWeeney, S. K., Eide, C. A., Nechiporuk, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08263-x · Cited by 158
Steudel, C., Wermke, M., Schaich, M. A., Schäkel, U., Illmer, T., Ehninger, G., & Thiede, C. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10219 · Cited by 156
Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G. M., Goldberg, S. L., Perl, A. E., Marie, J., Martinelli, G., Kantarjian, H. M., et al. (2018) · Blood · doi:10.1182/blood-2018-01-821629 · Cited by 156
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Luskin, M. R., Lee, J., Fernandez, H. F., Abdel-Wahab, O. I., Bennett, J. M., Ketterling, R. P., Lazarus, H. M., Levine, R. L., Litzow, M. R., Paietta, E. M., et al. (2016) · Blood · doi:10.1182/blood-2015-07-657403 · Cited by 128
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
Sakaguchi, M., Yamaguchi, H., Najima, Y., Usuki, K., Ueki, T., Oh, I., Mori, S., Kawata, E., Uoshima, N., Kobayashi, Y., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020305 · Cited by 127
Inhibition of c-Kit by tyrosine kinase inhibitors
Galanis, A., & Levis, M. J. (2014) · Haematologica · doi:10.3324/haematol.2014.117028 · Cited by 121
Park, I., Mishra, A., Chandler, J. C., Whitman, S. P., Marcucci, G., & Caligiuri, M. A. (2013) · Blood · doi:10.1182/blood-2012-07-444018 · Cited by 109
Meyer, S. E., Qin, T., Muench, D. E., Masuda, K., Venkatasubramanian, M., Orr, E., Suarez, L., Gore, S. D., Delwel, R., Paietta, E. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0008 · Cited by 105
Burchert, A., Bug, G., Finke, J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112614 · Cited by 105
Cortes, J. E., Kantarjian, H. M., Kadia, T. M., Borthakur, G. M., Konopleva, M. Y., Garcia‐Manero, G., Daver, N. G., Pemmaraju, N., Jabbour, E. J., Estrov, Z. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7008 · Cited by 102
Drug resistance in mutant FLT3-positive AML
Weisberg, E., Sattler, M., Ray, A., & Griffin, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.273 · Cited by 93
Chang, Y.-T., Hernandez, D., Alonso, S., Gao, M., Su, M., Ghiaur, G., Levis, M. J., & Jones, R. J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018022921 · Cited by 74
Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with FLT3 Mutation
Kiyoi, H., & Naoe, T. (2006) · International Journal of Hematology · doi:10.1532/ijh97.06071 · Cited by 67
Self-citationEffects of FLT3 Ligand on Proliferation and Survival of Myeloid Leukemia Cells
Drexler, H. G., Meyer, C., & Quentmeier, H. (1999) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199909093728 · Cited by 54
Harada, Y., Nagata, Y., Kihara, R., Ishikawa, Y., Asou, N., Ohtake, S., Miyawaki, S., Sakura, T., Ozawa, Y., Usui, N., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.008 · Cited by 52
Self-citationFLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.
Kiyoi, H. (2015) · PubMed Central · doi:10.18999/nagjms.77.1-2.7 · Cited by 47
Self-citationChen, F., Ishikawa, Y., Akashi, A., Naoe, T., & Kiyoi, H. (2016) · Oncotarget · doi:10.18632/oncotarget.10147 · Cited by 43
Self-citationKawashima, N., Akashi, A., Nagata, Y., Kihara, R., Ishikawa, Y., Asou, N., Ohtake, S., Miyawaki, S., Sakura, T., Ozawa, Y., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3492-5 · Cited by 25
Self-citation
Cited by
Erba, H. P., Montesinos, P., Kim, H.-J., Patkowska, E., Vrhovac, R., Žák, P., Wang, P.-N., Mitov, T., Hanyok, J., Kamel, Y. M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00464-6 · Cited by 418
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Metadata
- Authors
- Kiyoi, H., Kawashima, N., & Ishikawa, Y.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2019-12-30
- Volume
- 111
- Issue
- 2
- Pages
- 312-322
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2995587299
- Cited by
- 298
- References
- 77
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.